This company seems to have been delisted
Reason: Liquidation
Last recorded trade on: February 20, 2025
Source: https://globalgenes.org/raredaily/bellerophons-board-agrees-to-liquidate-after-trial-failures-and-layoffs/
Reason: Liquidation
Last recorded trade on: February 20, 2025
Source: https://globalgenes.org/raredaily/bellerophons-board-agrees-to-liquidate-after-trial-failures-and-layoffs/
Bellerophon Therapeutics
BLPH
₹1.03
Share price
-36.84%
Change (1 day)
-79.49%
Change (1 year)
Categories
Bellerophon Therapeutics (BLPH) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : ₹0.10 Billion
According to Bellerophon Therapeutics 's latest financial reports the company's total liabilities are ₹0.10 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Bellerophon Therapeutics - Total liabilities on balance sheet (from 2013 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | ₹0.44 B | 14.24% |
| 2021-12-31 | ₹0.39 B | -55.39% |
| 2020-12-31 | ₹0.87 B | 29.21% |
| 2019-12-31 | ₹0.67 B | -33.08% |
| 2018-12-31 | ₹1.01 B | -59.69% |
| 2017-12-31 | ₹2.51 B | 216.18% |
| 2016-12-31 | ₹0.79 B | 48.33% |
| 2015-12-31 | ₹0.53 B | -19.03% |
| 2014-12-31 | ₹0.66 B | -44.64% |
| 2013-12-31 | ₹1.19 B | 51.12% |
| 2012-12-31 | ₹0.79 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Baxter BAX | ₹1.220 T | 1,134,454.14% | 🇺🇸 USA |
 Abeona Therapeutics
ABEO | ₹4.96 B | 4,515.29% | 🇺🇸 USA |
 Abbott Laboratories ABT | ₹2.772 T | 2,578,243.95% | 🇺🇸 USA |
 Lantheus Holdings LNTH | ₹76.28 B | 70,841.88% | 🇺🇸 USA |